Cabozantinib is an oral small molecule inhibitor of VEGFR2 and MET among other tyrosine kinases29, and is FDA-approved for several indications: medullary thyroid cancer30, renal cell carcinoma (RCC)31, and advanced hepatocellular carcinoma (HCC)32. Here, MET is linked to hepatocellular carcinoma.